Charles Schwab Investment Management Inc Editas Medicine, Inc. Transaction History

Charles Schwab Investment Management Inc

  • $515 Billion
  • Q3 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 617,280 shares of EDIT stock, worth $746,908. This represents 0.0% of its overall portfolio holdings.

Number of Shares
617,280
Previous 733,385 15.83%
Holding current value
$746,908
Previous $3.42 Million 38.55%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
SELL
$3.39 - $5.96 $393,595 - $691,985
-116,105 Reduced 15.83%
617,280 $2.1 Million
Q2 2024

Aug 12, 2024
SELL
$4.67 - $7.28 $573,055 - $893,328
-122,710 Reduced 14.33%
733,385 $3.42 Million
Q1 2024

May 08, 2024
BUY
$7.03 - $11.07 $1.21 Million - $1.9 Million
172,079 Added 25.16%
856,095 $6.35 Million
Q4 2023

Feb 06, 2024
SELL
$6.25 - $11.11 $30,925 - $54,972
-4,948 Reduced 0.72%
684,016 $6.93 Million
Q3 2023

Nov 08, 2023
BUY
$6.92 - $9.31 $1.18 Million - $1.59 Million
170,694 Added 32.94%
688,964 $5.37 Million
Q2 2023

Aug 09, 2023
BUY
$6.36 - $11.47 $31,291 - $56,432
4,920 Added 0.96%
518,270 $4.27 Million
Q1 2023

May 11, 2023
BUY
$7.03 - $11.53 $25,244 - $41,404
3,591 Added 0.7%
513,350 $3.72 Million
Q4 2022

Feb 13, 2023
BUY
$8.32 - $13.21 $85,720 - $136,102
10,303 Added 2.06%
509,759 $4.52 Million
Q3 2022

Nov 14, 2022
BUY
$12.16 - $19.42 $153,556 - $245,235
12,628 Added 2.59%
499,456 $6.11 Million
Q2 2022

Aug 15, 2022
SELL
$9.99 - $21.35 $107,352 - $229,427
-10,746 Reduced 2.16%
486,828 $5.76 Million
Q1 2022

May 13, 2022
BUY
$14.08 - $27.63 $180,055 - $353,332
12,788 Added 2.64%
497,574 $9.46 Million
Q4 2021

Feb 11, 2022
BUY
$26.55 - $40.57 $257,508 - $393,488
9,699 Added 2.04%
484,786 $12.9 Million
Q3 2021

Nov 16, 2021
SELL
$39.27 - $72.94 $708,744 - $1.32 Million
-18,048 Reduced 3.66%
475,087 $19.5 Million
Q2 2021

Aug 16, 2021
BUY
$31.29 - $56.64 $378,515 - $685,174
12,097 Added 2.51%
493,135 $27.9 Million
Q1 2021

May 17, 2021
BUY
$39.71 - $90.58 $2.71 Million - $6.19 Million
68,350 Added 16.56%
481,038 $20.2 Million
Q4 2020

Feb 16, 2021
BUY
$27.07 - $84.35 $136,324 - $424,786
5,036 Added 1.24%
412,688 $28.9 Million
Q3 2020

Nov 13, 2020
BUY
$28.06 - $37.16 $391,016 - $517,824
13,935 Added 3.54%
407,652 $11.4 Million
Q2 2020

Aug 14, 2020
BUY
$18.5 - $34.34 $1.06 Million - $1.97 Million
57,361 Added 17.05%
393,717 $11.6 Million
Q1 2020

May 15, 2020
BUY
$14.88 - $32.78 $302,882 - $667,236
20,355 Added 6.44%
336,356 $6.67 Million
Q4 2019

Feb 07, 2020
BUY
$19.49 - $32.63 $327,782 - $548,771
16,818 Added 5.62%
316,001 $9.36 Million
Q3 2019

Nov 08, 2019
BUY
$22.49 - $26.81 $689,228 - $821,619
30,646 Added 11.41%
299,183 $6.8 Million
Q2 2019

Aug 09, 2019
BUY
$20.48 - $27.76 $297,267 - $402,936
14,515 Added 5.71%
268,537 $6.64 Million
Q1 2019

May 14, 2019
BUY
$19.43 - $26.41 $221,346 - $300,862
11,392 Added 4.7%
254,022 $6.21 Million
Q4 2018

Feb 14, 2019
SELL
$18.19 - $31.79 $4,110 - $7,184
-226 Reduced 0.09%
242,630 $5.52 Million
Q3 2018

Nov 13, 2018
BUY
$27.65 - $38.39 $798,836 - $1.11 Million
28,891 Added 13.5%
242,856 $7.73 Million
Q2 2018

Aug 08, 2018
BUY
$31.4 - $41.01 $941,403 - $1.23 Million
29,981 Added 16.3%
213,965 $7.67 Million
Q1 2018

May 07, 2018
BUY
$29.84 - $44.08 $1.38 Million - $2.04 Million
46,209 Added 33.54%
183,984 $6.1 Million
Q4 2017

Jan 17, 2018
BUY
$21.89 - $31.34 $454,502 - $650,712
20,763 Added 17.74%
137,775 $4.23 Million
Q3 2017

Nov 13, 2017
BUY
$15.81 - $24.01 $1.85 Million - $2.81 Million
117,012
117,012 $2.81 Million

Others Institutions Holding EDIT

# of Institutions
248
Shares Held
57M
Call Options Held
410K
Put Options Held
394K
View Full List

About Editas Medicine, Inc.

EDIT Quotes by TradingView
  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $83.2M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email